[Recent advances in molecular pathophysiology in diffuse large B-cell lymphoma and high-grade B-cell lymphoma]

Diffuse large B-cell lymphoma (DLBCL) represents a largest number of entities among lymphoid cancers, which are an aggregate of clinically and biologically diverse diseases. In particular, it is believed that various molecular genetic abnormalities are involved in the tumorigenesis of disease development. Owing to recent developments in multiomics analyses, gene expression profile reflecting cell-of-origin and tumor microenvironment and recurrent genetic abnormalities have been discovered; this is an important aspect for the development of future new therapeutic drugs and indications for clinical trials, ultimately encouraging precision medicine in the area of DLBCL. Here, we discuss the possibility of patient stratification based on genetic abnormality.